Faust changes name to Domain Therapeutics
This article was originally published in Scrip
Faust Pharmaceuticals has changed its name to Domain Therapeutics to reflect its new business model and activities better. The company was previously focused on its G protein-coupled receptors (GCPR) technology to build its own pipeline, but will now give other companies involved in GCPR drug discovery access to this platform. Domain will explore other targets to concentrate on areas outside of central nervous system diseases. Domain hopes to raise funds and sign collaborations for its technology platformand build partnerships for its products.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.